Education
About Us
Working with TipRanks
Follow Us
Olema Pharmaceuticals (OLMA)
NASDAQ:OLMA
OLMA Stock Chart & Stats
$8.79
$0.55(10.50%)
At close: 4:00 PM EST
$8.79
$0.55(10.50%)
Day’s Range― - ―
52-Week Range$2.86 - $13.51
Previous CloseN/A
Volume1.27M
Average Volume (3M)1.39M
Market Cap
$551.13M
Enterprise Value$7.06M
Total Cash (Recent Filing)$361.91M
Total Debt (Recent Filing)$1.75M
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Nov 11, 2025EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding68,634,330
10 Day Avg. Volume1,760,233
30 Day Avg. Volume1,389,007
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.01
Enterprise Value/Revenue19.40
Enterprise Value/Gross Profit-172.22
Enterprise Value/Ebitda-0.05
Forecast
1Y Price Target
$23.60Price Target Upside168.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Clinical TrialsOlema announced impressive updated data from the Phase 1b/2 trial of palazestrant and ribociclib in patients with ER+/HER2- metastatic breast cancer.
Market ValuationOLMA shares are seen as undervalued, especially with the breast cancer opportunity of palazestrant monotherapy.
Strategic PartnershipsOlema announced a clinical trial collaboration and supply agreement with Pfizer's CDK4 inhibitor, atirmociclib, which could enhance the development path for Olema's oral SERD/CERAN, palazestrant.
Bears Say
Competitive LandscapeA question remains about the future of oral SERD + CDK4/6i combinations if Pfizer's atirmociclib + letrozole combination is successful in the corresponding Phase 3 trial.
Regulatory ChallengesA pivotal trial involving an oral SERD with atirmociclib might conflict with the FDA's view on novel-on-novel combinations in advanced/metastatic ER+ breast cancer.
Olema Pharmaceuticals News
OLMA FAQ
What was Olema Pharmaceuticals’s price range in the past 12 months?
Olema Pharmaceuticals lowest stock price was $2.86 and its highest was $13.51 in the past 12 months.
What is Olema Pharmaceuticals’s market cap?
Olema Pharmaceuticals’s market cap is $551.13M.
When is Olema Pharmaceuticals’s upcoming earnings report date?
Olema Pharmaceuticals’s upcoming earnings report date is Nov 11, 2025 which is in 12 days.
How were Olema Pharmaceuticals’s earnings last quarter?
Olema Pharmaceuticals released its earnings results on Aug 11, 2025. The company reported -$0.51 earnings per share for the quarter, missing the consensus estimate of -$0.376 by -$0.134.
Is Olema Pharmaceuticals overvalued?
According to Wall Street analysts Olema Pharmaceuticals’s price is currently Undervalued.
Does Olema Pharmaceuticals pay dividends?
Olema Pharmaceuticals does not currently pay dividends.
What is Olema Pharmaceuticals’s EPS estimate?
Olema Pharmaceuticals’s EPS estimate is -0.48.
How many shares outstanding does Olema Pharmaceuticals have?
Olema Pharmaceuticals has 68,634,330 shares outstanding.
What happened to Olema Pharmaceuticals’s price movement after its last earnings report?
Olema Pharmaceuticals reported an EPS of -$0.51 in its last earnings report, missing expectations of -$0.376. Following the earnings report the stock price went up 16.193%.
Which hedge fund is a major shareholder of Olema Pharmaceuticals?
Currently, no hedge funds are holding shares in OLMA
Olema Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.60 (168.49% Upside)
$23.60 (168.49% Upside)
Blogger Sentiment
Bullish
OLMA Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 2.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $204.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 13.7%
Last 30 Days ▲ 13.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-23.89%
12-Months-Change
Fundamentals
Return on Equity
-49.72%
Trailing 12-Months
Asset Growth
50.07%
Trailing 12-Months
Company Description
Olema Pharmaceuticals
Olema Pharmaceuticals, Inc. (OLMA) is a clinical-stage biopharmaceutical company focused on developing targeted therapies for women's cancers. The company's primary focus is on the discovery and development of therapies for hormone receptor-positive breast cancer. Olema's lead product candidate, OP-1250, is designed to be a potential best-in-class complete estrogen receptor antagonist (CERAN) that inhibits estrogen receptor-positive (ER+) cancer growth.
OLMA Stock 12 Month Forecast
Average Price Target
$23.60
▲(168.49% Upside)
Technical Analysis
Meiragtx Holdings
―
Arvinas Holding Company
―
Gossamer Bio
―
Keros Therapeutics
―
Compass Therapeutics
―
Ownership Overview
28.29% Insiders
8.40% Mutual Funds
<0.01% Other Institutional Investors
53.73% Public Companies and
Individual Investors